Zenas BioPharma, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Zenas BioPharma, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$10.00M	$5.00M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$383.06M	-$163.89M
Operating income as a percentage of revenue.	-3830.6%	-3277.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$377.70M	-$156.99M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-8.00	$-11.89
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-8.00	$-11.89

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$110.64M	$319.74M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$383.64M	$369.97M
All of the company's interest-bearing borrowings, short and long term combined.	$78.64M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$141.50M	$57.51M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$242.14M	$312.46M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$172.33M	-$119.67M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$18000	$131000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$172.35M	-$119.81M

Peer Comparison

	You	Peer avg
P/E	–	13.7
Revenue Growth	–	+85.6%
ROE	-199.0%	-11.9%